IMCD China strengthens its life science business with the acquisition of Daoqin
13 Dicembre 2024 - 7:00AM
UK Regulatory
IMCD China strengthens its life science business with the
acquisition of Daoqin
ROTTERDAM, The Netherlands (13 December 2024) –
IMCD N.V. ("IMCD" or "Company"), a global leading distribution
partner and formulator of speciality chemicals and ingredients,
today announces that IMCD has signed an agreement to acquire the
business of the food and nutraceutical ingredient distributor:
Daoqin Biological Technology (Shanghai) Co., Ltd., Longyu
International Trade (Shanghai) Co., Ltd. and Long’en Biotechnology
(Guangzhou) Co., Ltd. in China (jointly "Daoqin").
Established in 2011, Daoqin specialises in the distribution of
functional nutrition, nutraceutical and food ingredients. Daoqin
represents leading suppliers and offers, through its dedicated
technical team and its laboratory, innovative solutions to its
customers in the food, personal care and pharmaceutical industries.
Daoqin is headquartered in Shanghai, China, and generated a revenue
of approximately CNY 122 million (ca. EUR 16 million) in 2023 with
21 employees.
"The addition of Daoqin marks another step in our journey to
deepen our presence in the food and nutrition markets and broadens
the scope of our life science business portfolio," remarked Nicky
Huang, Managing Director of IMCD China. "With the acquisition of
Daoqin, we are very excited to welcome a very engaged and talented
team and leverage our complementary portfolios and technical
expertise to enhance our capabilities and offering in the local
market," concluded Huang.
“The Daoqin team is excited to join IMCD, as we believe there
are strong synergies between our businesses and capabilities,” said
Jack Ning, General Manager of Daoqin. “By leveraging IMCD's
exceptional global network and resources, we look forward to
bringing greater innovation and value to customers in the life
sciences markets in China.”
The closing of the transaction is subject to customary closing
conditions and is expected to take place in the second quarter of
2025.
Attached, the full press release in PDF format, the main visual
and photo caption.
- Photo_IMCD China strengthens its lifescience business with the
acquisition of Daoqin
- PR - IMCD China strengthens its life science business with the
acquisition of Daoqin
- Photo Caption_IMCD China strengthens its life science business
with the acquisition of Daoqin
Grafico Azioni IMCD NV (EU:IMCD)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni IMCD NV (EU:IMCD)
Storico
Da Dic 2023 a Dic 2024
